Trial Profile
Administration of EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Jul 2021
Price :
$35
*
At a glance
- Drugs Baltaleucel-T (Primary)
- Indications Epstein-Barr virus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ETNA
- 08 Aug 2014 New trial record